The Detection of Tramadol in Honey

Omar M. E. Abdel-Salam1*, Jihan Seid Hussein2, Shaimaa A. ElShebiney1



* Corresponding Author: Omar M. E. Abdel-Salam (MD, PhD)
Department of Toxicology and Narcotics
National Research Centre
Tahrir St., 12311, Dokki, Cairo, Egypt
omasalam@hotmail.com

Editor: Dr. Akshay Dwarakanath
Principal Scientist – Regulatory Toxicology
CSIR – Indian Institute of Toxicology Research, P.O. Box 80
M.G. Marg Lucknow – 226001, India.
Cite this Article: Abdel Salam OME, Hussein JS, and ElShebiney SA (2016) 'The Detection of Tramadol in Honey', ScholReps, 1(2), pp. 1-5.

Copyright:© 2016 Abdel Salam OME et. al. This is an open access article distributed under the terms of the Creative Commons Attribution 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Subject Section: Toxicology

Conflicts of Interest: The authors have read the journal’s policy and have the following conflicts:
Corresponding author Omar M. E. Abdel-Salam is editor of Scholars Report for Toxicology Section. This does not alter the authors’ adherence to all the Scholars Report policies on sharing data and materials. All other authors declare that no con¬flicts of interest exist.

Publication Details
Received: July 19, 2016                Revised(I): Aug 16, 2016                Revised(II): Sept 09, 2016                Accepted: Sept 12, 2016                Published: Sept 14, 2016

FundingNone

Abstract:
Tramadol is a centrally acting analgesic selective for the μ-opioid receptor with antidepressant and dopamine releasing actions. In Egypt, dependence on and abuse of tramadol presents a challenging health problem and the drug is included in the narcotic analgesic schedule III. In this study, a sample of commercially available honey was brought to the laboratory of narcotics and poisons on the suspicion of withdrawal symptoms upon discontinuation. The presence of tramadol was suspected and the sample was subjected to thin-layer chromatography (TLC) and high-performance liquid chromatography (HPLC). Liquid-liquid extraction was carried out using a mixture of chloroform and isopropanol (4:1, v/v)(3:1) in an alkaline medium (pH 8.5). The re-constituted residue was spotted on a TLC plate along with standard tramadol and sprayed with Dragendorff’s reagent. Honey samples were found positive for tramadol. Determination of tramadol was then carried out using HPLC. Separation was achieved on ODS-reversed phase column (C18, 25 x 0.46 cm i.d.5 µm).the mobile phase consisted of water/acetonitrile/triethylamine 40/60/0.1 v/v and was delivered at a flow rate of 2 ml/min. UV detection was performed at 280 nm, and the injection volume was 20µL. HPLC indicated the presence of tramadol HCl in honey. The concentration of tramadol in the sample was determined by an external standard method using peak area. The concentration of tramadol in the sample was then found to be 36.5 mg/ml. The present study is the first which describes the identification of tramadol in commercial honey.

Keywords: honey; tramadol; high-performance liquid chromatography

Introduction

Tramadol is a centrally-acting analgesic with opioid and non-opioid properties. In clinical practice, it is used worldwide for the prevention and treatment of moderate to severe pain in acute or chronic conditions [1]. This centrally acting analgesic is a synthetic 4-phenylpiperidine analog of codeine [2]. Tramadol is (1RS;2RS)-2-(dimethylaminomethyl)-1-(3-methoxyphenyl)-cyclohexanol-hydrochloride [3]. The drug is an opioid agonist with selectivity for the μ-opioid receptor [4]. In addition to its actions on brain opioid receptors, tramadol also inhibits the reuptake of serotonin and noradrenaline [5, 6]. Tramadol enhances dopamine release in specific brain areas, including medulla oblongata, hypothalamus, corpus striatum, and nucleus accumbens, which may mediate reinforcing effects [6]. In humans, tramadol (350 mg) induced miosis and mixed subjective effects, increasing the rating of “good effects” and “liking” as well as the unpleasant subjective effects. Only the pleasant effects were partially attenuated with the opioid antagonist naltrexone [7]. In recent years, there has been an increasingly growing number of human studies and cases reports of tramadol dependence, abuse, and intoxication [8-11]. The present study describes the identification of tramadol in commercial honey.


Materials and methods:

A sample of labeled honey jar was brought to the laboratory of narcotics and poisons to be verified for the presence of tramadol HCl (the narcotic analgesic schedule III). There consumers of the honey suspected the presence of a substance of abuse because of feeling unwell upon discontinuing ingesting the honey. We suspected the presence of tramadol based on its widespread abuse in Egypt [12-15].

Preparation of standard solution

A stock solution of tramadol (1 mg/ml) was prepared in 10 ml volumetric flask with methanol and stored at 4C. Working solutions for calibration curve were prepared using methanol (HPLC grade).

Preparation of sample

A sample of labeled honey jar was submitted to the laboratory of narcotics and poisons to be verified for the presence of tramadol HCl (the narcotic analgesic schedule III). First, the sample was examined for its characteristics (viscosity, color, and odor) and it showed normal features of honey.

Liquid-liquid extraction was carried out using a mixture of chloroform and isopropanol (4:1, v/v) (3:1) in an alkaline medium (pH 8.5). Briefly, 100 ml of honey was diluted with 20 ml of distilled water and alkalinized by sodium hydroxide (10N) to pH 8.5(10), then well-shaken with 50 ml of chloroform mixture for 10 min and repeated three times. The final organic phase was transferred to a flask and evaporated under a gentle stream of nitrogen then the residue was re-constituted in 1ml (10 ml) of methanol (HPLC grade). The re-constituted residue was spotted on TLC plate along with standard tramadol and sprayed with Dragendorff’s reagent.

A 20 µL aliquot of the solution was injected into the HPLC system.


Results and discussion

Thin layer chromatography

The spotted sample had the same hRf value of the standard and gave the same orange-red color with Dragendorff’s spray reagent.

High-performance liquid chromatography (HPLC)

Determination of tramadol was carried out using HPLC, Agilent technologies 1100 series equipped with a quaternary pump (Quat pump, G 131A model). Separation was achieved on ODS-reversed phase column (C18, 25 x 0.46 cm i.d.5 µm). The mobile phase consisted of water/acetonitrile/triethylamine 40/60/0.1 v/v and was delivered at a flow rate of 2 ml/min. UV detection was performed at 280 nm, and the injection volume was 20µL.

The concentration of tramadol in the sample was determined by an external standard method using peak area. Serial dilutions of the standard were injected and their peak areas were determined. A linear standard curve was constructed by plotting peak areas versus the corresponding concentrations. The concentration of tramadol in the sample was then obtained from the curve and was found to be 36.5 mg/ml.

Figure 1: HPLC chromatogram showing tramadol standard peak at a retention time 3.9 min.

Figure 2: HPLC chromatogram showing tramadol peak in a honey sample at a retention time 3.9 min.


Discussion

In the present study, we describe the first identification of tramadol in a sample of commercially available honey. The sample was brought to our laboratory suspecting the presence of a drug of abuse because of the awareness of the consumers of withdrawal symptoms when discontinuing ingesting the honey. Since abuse of and dependence on tramadol is a widespread health problem in Egypt [12-15], the presence of tramadol was initially suspected and later proved to be the case.

The abuse of tramadol is a growing health concern worldwide [8-11]. The drug is a potent centrally-acting analgesic owing to a selective action on μ-opioid receptors [1]. It is used to alleviate moderate-to-severe pain [4]. Side effects of the drug include nausea, vomiting, dizziness, drowsiness, and orthostatic hypotension [16]. In addition, severe hyponatraemia [17] and generalized tonic-clonic seizures have also been described with high doses of tramadol [10]. Overdose can cause ventricular tachycardia and, cardiac arrest in asystole with refractory shock [18, 19].

Tramadol dependence does occur within the recommended therapeutic doses and could be severe in those who are susceptible [20]. Even after disease regression, the patient usually continues to take the drug because of a feeling of well-being [21, 22]. The drug inhibits neuronal reuptake of noradrenaline and serotonin thereby enhancing monoaminergic neurotransmission [5,6]. The agent is thus likely to have antidepressant properties and this might be one reason which accounts for the continued intake of tramadol because of a mood enhancing effect (to improve mood) despite pain regression [23, 24]. Withdrawal symptoms occur after tramadol discontinuation. Mostly, withdrawal symptoms are those of classical opioid withdrawal (eg., abdominal cramps, anxiety, depression). However, atypical withdrawal symptoms might occur including hallucinations, delusions, paranoia, panic attacks, and confusion [25] or even seizures [26].

The importance of the present finding of tramadol in honey also derives from the ability of the drug to cause serotonin-like syndrome if taken with other drugs that increase serotonin activity [27]. The latter is a life-threatening condition resulting from excessive stimulation of serotonergic neurotransmission with disorientation, agitation, restlessness, tremors, seizures, coma, cardiac arrhythmia, and hypertension [28]. Serotonin syndrome has been reported following treatment with tramadol and either selective serotonin-reuptake inhibitors [29] or the atypical antipsychotic ziprasidone [30].


Conclusions

The present study describes the identification of tramadol in commercial honey. This finding should alarm authorities on the ways used to introduce this drug with addiction liability into food.

Acknowledgment

The authors acknowledge The National Research Centre (NRC), Cairo, Egypt, for financial support.

Declaration

On behalf of all Co-Authors, the corresponding Author, states that this research work is original and has not been published in whole or in part elsewhere.

Authorship (author(s) contribution or attribution)

All Authors listed on the title page have contributed significantly to the work, have read the manuscript, attest to the validity and legitimacy of the data and its interpretation, agree to its content and submission to ScholReps and approved the version to be published.


References

  1. Reeves RR, Burke RS. (2008). Tramadol: basic pharmacology and emerging concepts. Drugs Today (Barc). 44(11),827-836.
    PMID: 19180260 doi: 10.1358/dot.2008.44.11.1289441.

  2. Hammonds B, Sidebotham DA, Anderson BJ. (2003). Aspects of tramadol and ondansetron interactions. Acute Pain. 5,31–34 .

  3. Matthiesen T, Wöhrmann T, Coogan TP, Uragg H. (1998). The experimental toxicology of tramadol: an overview. Toxicology Letters. 95(1), 63-71.
    PMID: 9650647

  4. Radbruch L, Grond S, Lehmann KA. (1996). A risk-benefit assessment of tramadol in the management of pain. Drug Safety. 15(1), 8-29.
    PMID: 8862961

  5. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B. (1996). Influence of tramadol on neurotransmitter systems of the rat
    brain. Arzneimittelforschung. 46(11):1029-36. PMID: 8955860

  6. Sprague JE, Leifheit M, Selken J, Milks MM, Kinder DH, Nichols DE. (2002). In vivo microdialysis and conditioned place preference studies in rats are consistent with abuse potential of tramadol. Synapse. 43(2),118-121.
    PMID: 11754490 doi: 10.1002/syn.10025

  7. Stoops WW, Lofwall MR, Nuzzo PA, Craig LB, Siegel AJ, Walsh SL. (2012). Pharmacodynamic profile of tramadol in humans: influence of naltrexone pretreatment. Psychopharmacology (Berl). 223(4),427-438.
    PMID: 22623016 doi: 10.1007/s00213-012-2739-4 PMCID: PMC3439600

  8. Lanier RK, Lofwall MR, Mintzer MZ, Bigelow GE, Strain EC. (2010). Physical dependence potential of daily tramadol dosing in humans. Psychopharmacology (Berl). 211(4),457-466.
    PMID: 20589494 doi: 10.1007/s00213-010-1919-3 PMCID: PMC3028382

  9. Zhang H, Liu Z. (2013). The investigation of tramadol dependence with no history of substance abuse: a cross-sectional survey of spontaneously reported cases in Guangzhou City, China. Biomed Res Int. 2013,283425.
    PMID: 24151592 doi: 10.1155/2013/283425 PMCID: PMC3787562

  10. Bekjarovski N, Chaparoska D, Radulovikj-Bekjarovska S. (2012). Seizures after use and abuse of tramadol. Prilozi. 33(1),313-318.
    PMID: 22983066

  11. Stoehr JD, Essary AC, Ou C, Ashby R, Sucher M. (2009). The risk of tramadol abuse and dependence: findings in two patients. JAAPA. 22(7), 31-2, 34-5.
    PMID: 19697569

  12. Shalaby AS, El-Hady Sweilum OA, Ads MK.(2015). Does tramadol increase the severity of nicotine dependence? A study in an Egyptian sample. J Psychoactive Drugs. 47(3),197-202.
    PMID: 26121025 doi: 10.1080/02791072.2015.1050534

  13. El-Hadidy MA, Helaly AM.(2015). Medical and psychiatric effects of long-term dependence on high dose of tramadol. Subst Use Misuse. 50(5), 582-589.
    PMID: 25544109 doi: 10.3109/10826084.2014.991406

  14. Bassiony MM, Salah El-Deen GM, Yousef U, Raya Y, Abdel-Ghani MM, El-Gohari H, Atwa SA. (2015). Adolescent tramadol use and abuse in Egypt. Am J Drug Alcohol Abuse. 41(3),206-211.
    PMID: 25859610 doi: 10.3109/00952990.2015.1014959

  15. Loffredo CA, Boulos DN, Saleh DA, Jillson IA, Garas M, Loza N, Samuel P, Shaker YE, Ostrowski MJ, Amr S. 92015). Substance use by Egyptian youth: current patterns and potential avenues for prevention. Subst Use Misuse. 50(5),609-18.
    PMID: 25629955 doi: 10.3109/10826084.2014.997391

  16. Leppert W. (2009).Tramadol as an analgesic for mild to moderate cancer pain. Pharmacol Rep. 61(6),978-992.
    PMID: 20081232

  17. Lota AS, Dubrey SW, Wills P. (2012). Profound hyponatraemia following a tramadol overdose. QJM. 105(4), 397-398.
    PMID: 22328544 doi: 10.1093/qjmed/hcs027

  18. Daubin C, Quentin C, Goullé JP, Guillotin D, Lehoux P, Lepage O, Charbonneau P .(2007). Refractory shock and asystole related to tramadol overdose. Clin Toxicol (Phila). 45(8), 961-964.
    PMID: 17852155 doi: 10.1080/15563650701438847

  19. Perdreau E, Iriart X, Mouton JB, Jalal Z, Thambo JB. (2015). Cardiogenic shock due to acute tramadol intoxication. Cardiovasc Toxicol. 15(1),100-103.
    PMID: 24811952 doi: 10.1007/s12012-014-9262-2

  20. Tjäderborn M, Jönsson AK, Ahlner J, Hägg S. (2009). Tramadol dependence: a survey of spontaneously reported cases in Sweden. Pharmacoepidemiol Drug Saf. 18(12), 1192-8.
    PMID: 19827010 doi: 10.1002/pds.1838

  21. Pollice R, Casacchia M, Bianchini V, Mazza M, Conti CM, Roncone R. (2008). Severe tramadol addiction in a 61 year-old woman without a history of substance abuse. Int J Immunopathol Pharmacol. 21(2),475-476.
    PMID: 18547496

  22. Khan NA, Sullivan MA, Vitale MG, Tresgallo ME, Saroyan JM. (2013). Undetected Ultracet™ dependence in an adolescent with nonmalignant back pain. J Opioid Manag. 9(3),225-230.
    PMID: 23771572 doi: 10.5055/jom.2013.0163

  23. Barber J. (2011). Examining the use of tramadol hydrochloride as an antidepressant. Exp Clin Psychopharmacol. 19(2),123-130.
    PMID: 21463069 doi: 10.1037/a0022721

  24. Ferrari A, Tiraferri I, Palazzoli F, Licata M. (2014). Tramadol abuse in a binge pattern in a young depressed woman. Eur Addict Res. 20(2), 82-86.
    PMID: 24080865 doi: 10.1159/000353971

  25. Senay EC, Adams EH, Geller A, Inciardi JA, Muñoz A, Schnoll SH, Woody GE, Cicero TJ. (2003). Physical dependence on Ultram (tramadol hydrochloride): both opioid-like and atypical withdrawal symptoms occur. Drug Alcohol Depend. 69(3), 233-241.
    PMID: 12633909

  26. Choong K, Ghiculescu RA. (2008). Iatrogenic neuropsychiatric syndromes.Aust Fam Physician. 37(8), 627-629.
    PMID: 18704211

  27. Beakley BD, Kaye AM, Kaye AD. (2015). Tramadol, pharmacology, side effects, and serotonin syndrome: A review. Pain Physician.18(4), 395-400.
    PMID: 26218943

  28. Volpi-Abadie J, Kaye AM, Kaye AD. (2013). Serotonin syndrome. The Ochsner Journal. 13(4), 533-540.
    PMID: 24358002 PMCID: PMC3865832

  29. Nelson EM, Philbrick AM. (2012). Avoiding serotonin syndrome: the nature of the interaction between tramadol and selective serotonin reuptake inhibitors. Ann Pharmacother. 46(12):1712-6.
    PMID: 23212934 doi: 10.1345/aph.1Q748

  30. El-Okdi NS, Lumbrezer D, Karanovic D, Ghose A, Assaly R. (2014). Serotonin syndrome after the use of tramadol and ziprasidone in a patient with a deep brain stimulator for Parkinson disease. Am J Ther. 21, e97-9.
    PMID: 24158007 doi: 10.1097/MJT.0b013e3182456d88


Click to Print This Page